Atrium Therapeutics completes $50 million private placement financing
1 report, 1 independent
Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Atrium Therapeutics announced it entered into a securities purchase agreement for a private placement financing with institutional investors. The placement is expected to generate approximately $50 million in gross proceeds before deducting fees. The company agreed to issue 5,170,384 shares of common stock and pre-funded warrants at the market price.
From prnewswire.com
Why it matters
The financing is intended to fund Atrium Therapeutics' operations through 2028. The transaction involved participation from several institutional investors, including Sirenia Capital Management LP, Aberdeen Investments, and Casdin Capital.
From prnewswire.com
Who's involved
- AtriumBiopharmaceutical company raising capital for operations
- Leerink partnersLead placement agent for Atrium Therapeutics
- Cantor FitzgeraldPlacement agent for Atrium Therapeutics
- BarclaysPlacement agent for Atrium Therapeutics
Keep exploring
The entities involved
-
Atrium
Nothing else this week.
-
Leerink partners
U.S. investment bank
-
Cantor Fitzgerald
American financial services company